The application of nanoparticles as advanced drug delivery systems in Attenuating COPD

Victoria Jessamine; Samir Mehndiratta; Gabriele De Rubis; Keshav Raj Paudel; Saritha Shetty; Divya Suares; Dinesh Kumar Chellappan; Brian G Oliver; Phillip M Hansbro; Kamal Dua

doi:10.1016/j.heliyon.2024.e25393

The application of nanoparticles as advanced drug delivery systems in Attenuating COPD

Heliyon. 2024 Feb 1;10(3):e25393. doi: 10.1016/j.heliyon.2024.e25393. eCollection 2024 Feb 15.

Authors

Victoria Jessamine¹, Samir Mehndiratta^{1

2}, Gabriele De Rubis^{1

2}, Keshav Raj Paudel^{2

3}, Saritha Shetty⁴, Divya Suares⁴, Dinesh Kumar Chellappan⁵, Brian G Oliver^{6

7}, Phillip M Hansbro³, Kamal Dua^{1

2}

Affiliations

¹ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia.
² Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
³ Centre for Inflammation, Centenary Institute and University of technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, 2007, Australia.
⁴ Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's, NMIMS Deemed to Be University, Mumbai, 400056, Maharashtra, India.
⁵ Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 578000, Malaysia.
⁶ School of Life Sciences, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
⁷ Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a dilapidating condition which is characterized by inflammation, an excess in free radical generation and airway obstruction. Currently, the drugs commercially available for the management of COPD pose several limitations such as systemic adverse effects, including bone density loss and an increased risk of developing pneumonia. Moreover, another limitation includes the need for regular and frequent dosing regimens; which can affect the adherence to the therapy. Furthermore, these current treatments provide symptomatic relief; however, they cannot stop the progression of COPD. Comparatively, nanoparticles (NPs) provide great therapeutic potential to treat COPD due to their high specificity, biocompatibility, and higher bioavailability. Furthermore, the NP-based drug delivery systems involve less frequent dosing requirements and in smaller doses which assist in minimizing side effects. In this review, the benefits and limitations of conventional therapies are explored, while providing an in-depth insight on advanced applications of NP-based systems in the treatment of COPD.

Keywords: COPD; Clinical trials; Drug delivery; Inhaled corticosteroids; Nanoparticles; Polymeric nanoparticles; miRNA nanotherapeutics.

Publication types

Review